EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOKIG00005019723
Gene Symbol: NTRK2
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOKIG00005044741
Gene Symbol: NTRK3
1 Cross references
192 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOKIG00005040435
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOKIG00005024065
Gene Symbol: NTRK1
1 Cross references
193 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOKIG00005028828
Gene Symbol: NTRK1
1 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOKIG00005008221
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOKIG00005010857
Gene Symbol: NTRK2B
1 Cross references
204 Possible Orthologues:

Nicastrin

Ensembl ID : ENSOKIG00005038937
Gene Symbol: NCSTN
3 Cross references
197 Possible Orthologues:

Nicastrin

Ensembl ID : ENSOKIG00005018137
Gene Symbol: NCSTN
3 Cross references
197 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOKIG00005029903
Gene Symbol: NAMPT
3 Cross references
154 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOKIG00005001911
Gene Symbol: NAMPT
3 Cross references
220 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOKIG00005026646
Gene Symbol: NAMPT
3 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).